benzethonium has been researched along with Leishmaniasis, Cutaneous in 15 studies
Benzethonium: Bactericidal cationic quaternary ammonium surfactant used as a topical anti-infective agent. It is an ingredient in medicaments, deodorants, mouthwashes, etc., and is used to disinfect apparatus, etc., in the food processing and pharmaceutical industries, in surgery, and also as a preservative. The compound is toxic orally as a result of neuromuscular blockade.
Leishmaniasis, Cutaneous: An endemic disease that is characterized by the development of single or multiple localized lesions on exposed areas of skin that typically ulcerate. The disease has been divided into Old and New World forms. Old World leishmaniasis is separated into three distinct types according to epidemiology and clinical manifestations and is caused by species of the L. tropica and L. aethiopica complexes as well as by species of the L. major genus. New World leishmaniasis, also called American leishmaniasis, occurs in South and Central America and is caused by species of the L. mexicana or L. braziliensis complexes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Paromomycin (PR) has been developed as an alternative to SbV, but existing data are conflicting." | 2.45 | Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. ( Bleys, J; Chung, HJ; Ghohestani, RF; Kim, DH, 2009) |
| " Imiquimod (5-10 microg/ml) combined with either paromomycin (25, 50 and 100 microg/ml) or methylbenzethonium chloride (0." | 1.34 | Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator Imiquimod. ( Bazarsky, E; El-On, J; Sneir, R, 2007) |
| "Cutaneous leishmaniasis is presently treated with 20 days of parenteral therapy with a frequently toxic drug (antimony)." | 1.30 | Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin. ( Berman, JD; Ellis, WY; Grogl, M; Schuster, BG, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (60.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Livneh, A | 1 |
| Youngster, I | 1 |
| El-On, Y | 1 |
| Berkovitch, M | 1 |
| Abu-Kishk, I | 1 |
| Kim, DH | 1 |
| Chung, HJ | 1 |
| Bleys, J | 1 |
| Ghohestani, RF | 1 |
| Armijos, RX | 1 |
| Weigel, MM | 1 |
| Calvopiña, M | 1 |
| Mancheno, M | 1 |
| Rodriguez, R | 1 |
| El-On, J | 4 |
| Bazarsky, E | 1 |
| Sneir, R | 1 |
| Iqbal, J | 1 |
| Bukhari, I | 1 |
| Jamshid, M | 1 |
| Bashir, S | 1 |
| Masoom Yasinzai, M | 1 |
| Anwar, M | 1 |
| Soto, J | 2 |
| Hernandez, N | 1 |
| Mejia, H | 1 |
| Grogl, M | 2 |
| Berman, J | 2 |
| Schallreuter, KU | 1 |
| Lemke, KR | 1 |
| Fuya, P | 1 |
| Herrera, R | 1 |
| Grunwald, MH | 2 |
| Amichai, B | 1 |
| Trau, H | 1 |
| Schuster, BG | 1 |
| Ellis, WY | 1 |
| Berman, JD | 1 |
| Krause, G | 1 |
| Kroeger, A | 2 |
| Arana, BA | 1 |
| Mendoza, CE | 1 |
| Rizzo, NR | 1 |
| Sneier, R | 1 |
| Elias, E | 1 |
| Halevy, S | 1 |
| Weinrauch, L | 1 |
| Sulitzeanu, A | 1 |
| Schnur, LF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Paromomycin Topical Cream Treatment Protocol for Individuals With Uncomplicated Cutaneous Leishmaniasis[NCT01641796] | 0 participants | Expanded Access | No longer available | ||||
| Active Surveillance for Cutaneous Leishmaniasis in Mali[NCT00344084] | 1,593 participants (Actual) | Observational | 2006-03-16 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for benzethonium and Leishmaniasis, Cutaneous
| Article | Year |
|---|---|
Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials.
Topics: Antiprotozoal Agents; Benzethonium; Humans; Leishmaniasis, Cutaneous; Paromomycin; Randomized Contro | 2009 |
5 trials available for benzethonium and Leishmaniasis, Cutaneous
| Article | Year |
|---|---|
Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.
Topics: Administration, Topical; Adolescent; Adult; Animals; Antiprotozoal Agents; Benzethonium; Double-Blin | 2004 |
Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate.
Topics: Administration, Topical; Adolescent; Adult; Animals; Antiprotozoal Agents; Benzethonium; Drug Admini | 1995 |
Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study.
Topics: Antiprotozoal Agents; Benzethonium; Double-Blind Method; Drug Therapy, Combination; Humans; Leishman | 1998 |
Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala.
Topics: Adolescent; Adult; Antiprotozoal Agents; Benzethonium; Child; Double-Blind Method; Drug Therapy, Com | 2001 |
Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study.
Topics: Administration, Cutaneous; Adolescent; Adult; Animals; Anti-Infective Agents, Local; Benzethonium; C | 1992 |
9 other studies available for benzethonium and Leishmaniasis, Cutaneous
| Article | Year |
|---|---|
The lack of effectiveness of hyperbaric oxygenation as a treatment for Leishmania major in a mouse model.
Topics: Animals; Antiprotozoal Agents; Benzethonium; Disease Models, Animal; Drug Therapy, Combination; Hype | 2015 |
Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator Imiquimod.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Antiprotozoal Agents; Benzethonium; Drug Therapy, | 2007 |
Hexadecyl-phosphorylcholine ointment for treatment of cutaneous leishmaniasis: an animal trial.
Topics: Administration, Cutaneous; Analysis of Variance; Animals; Anti-Infective Agents, Local; Antiprotozoa | 2006 |
[Successful topical treatment of chronic cutaneous leishmaniasis with paromomycin sulfate (15%) and methylbenzethonium chloride (12%)].
Topics: Administration, Topical; Adult; Antiprotozoal Agents; Benzethonium; Drug Administration Schedule; Dr | 1994 |
Cutaneous leishmaniasis on an unusual site--the glans penis.
Topics: Adult; Anti-Bacterial Agents; Benzethonium; Humans; Leishmaniasis, Cutaneous; Male; Ointments; Parom | 1998 |
Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin.
Topics: Administration, Topical; Animals; Antiprotozoal Agents; Benzethonium; Cricetinae; Drug Therapy, Comb | 1999 |
Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment of American cutaneous leishmaniasis: controlled study.
Topics: Administration, Topical; Anti-Bacterial Agents; Anti-Infective Agents, Local; Antiprotozoal Agents; | 1999 |
Leishmania major: bacterial contamination of cutaneous lesions in experimental animals.
Topics: Animals; Anti-Infective Agents, Local; Bacterial Infections; Benzethonium; Disease Models, Animal; D | 1992 |
Leishmania major: resistance of promastigotes to paromomycin, and susceptibility of amastigotes to paromomycin-methylbenzethonium chloride ointment.
Topics: Administration, Topical; Animals; Anti-Infective Agents, Local; Benzethonium; Drug Resistance; Drug | 1991 |